首页> 美国卫生研究院文献>Oncotarget >Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF
【2h】

Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF

机译:人源化抗肝细胞生长因子(HGF)抗体抑制成纤维细胞衍生HGF诱导的先天伊立替康(CPT-11)耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The growth factors derived from the microenvironment create an environment conducive to tumor growth and survival. HGF deprivation using neutralizing antibody enhanced chemosensitivity in colorectal cancer cells (CRC). We determined secreted HGF in fibroblast conditioned medium (CM). Combination treatment of anti-HGF antibody and irinotecan (CPT-11) directly enhanced CPT-11 sensitivity in CRC. We generated xenograft in NOD/SCID mice inoculating HCT-116 human colorectal cancer cells subcutaneously with or without fibroblast. We found that the combination of CPT-11 and anti-HGF antibody induced marked suppression of tumor development. These results suggest that HGF produced by fibroblast induce CPT-11 resistance, and that anti-HGF antibody abrogate such resistance in vivo. fibroblast-derived HGF is important determinant of chemoresistance. Anti-HGF monoclonal antibody treatment confirmed the importance of this growth factor for chemoresistance in CRC. These results present new options toward the early diagnosis of chemoresistance and suggest novel combinations of chemotherapy and anti-HGF agents to prevent or significantly delay the onset of therapy resistance.
机译:源自微环境的生长因子创造了有利于肿瘤生长和存活的环境。使用中和抗体的HGF剥夺增强了结直肠癌细胞(CRC)的化学敏感性。我们确定了成纤维细胞条件培养基(CM)中分泌的HGF。抗HGF抗体和伊立替康(CPT-11)的联合治疗可直接增强CRC中CPT-11的敏感性。我们在有或没有成纤维细胞的皮下接种HCT-116人结肠直肠癌细胞的NOD / SCID小鼠体内产生了异种移植物。我们发现CPT-11和抗HGF抗体的组合可显着抑制肿瘤的发展。这些结果表明由成纤维细胞产生的HGF诱导CPT-11抗性,并且抗HGF抗体在体内消除了这种抗性。成纤维细胞衍生的HGF是化学抗性的重要决定因素。抗HGF单克隆抗体治疗证实了该生长因子对于CRC耐药的重要性。这些结果为化学耐药性的早期诊断提供了新的选择,并提出了化学疗法和抗HGF药物的新组合,可预防或显着延迟治疗耐药性的发作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号